Improving Migraine Care: Migraine Comorbidity Assessment
May 28, 2020
May 28, 2021
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Albert Einstein College of Medicine-Montefiore Medical Center.
Supported by an educational grant from Amgen.
- Physicians — maximum of 0.50 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
Neurologists, Primary care providers, Emergency medicine providers, Nurse practitioners, Physician assistants, Nurses
Upon completion of this activity, participants should be able to:
- Incorporate evidence-based screening for comorbidities in all migraine patients
- Select treatment to manage comorbidities and migraine
Jessica Ailani, MD, FAHS, FAAN
Director, MedStar Georgetown Headache Center
Professor of Clinical Neurology
Department of Neurology
MedStar Georgetown University Hospital
David M. Kaufman, MD
Professor of Neurology and Psychiatry
Albert Einstein College of Medicine
Montefiore Medical Center
Joint Accreditation Statement
In support of improving patient care, Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Credit Designation Statement
Albert Einstein College of Medicine-Montefiore Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Disclosures of Conflicts of Interest
Albert Einstein College of Medicine-Montefiore Medical Center requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. The Albert Einstein College of Medicine-Montefiore Medical Center also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device, not yet approved in the United States. All identified COI are thoroughly vetted and resolved according to Albert Einstein College of Medicine-Montefiore Medical Center policy. Albert Einstein College of Medicine-Montefiore Medical Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Jessica Ailani, MD, FAHS, FAAN has disclosed that she has received consulting fees from Allergan, Amgen, Biohaven, Impel, Lilly, Lundbeck, Revance, Satsuma, Teva, Theranica, and Zosano; funds for research support from Allergan, Biohaven, Lilly, and Zosano; and fees for non-CME/CE services from Allergan, Amgen, Biohaven, Lilly, Lundbeck, and Teva.
The planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Wendy Gloffke, PhD, has no relevant conflicts of interest to report.
- Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
- Anne Roc, PhD, has no relevant conflicts of interest to report.
- David Kaufman, MD has no relevant conflicts of interest to report.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.